BioPharma Dive - Latest News

BridgeBio’s heart drug launch gets off to a fast start

Prescription totals for Attruby, which is locked in a closely watched commercial...

Sanofi reaches consumer health deal; Supernus antidepre...

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella u...

FTC retains stricter merger guidelines under Trump

Agency chair Andrew Ferguson sent a memo to staff on Tuesday clarifying that Bid...

Recursion CEO launches pre-seed fund in response to NIH...

Chris Gibson, Recursion’s head, cited the role small business grants played in h...

Biogen buys rights to Stoke’s rare epilepsy drug

In exchange for $165 million, Biogen now has access to zorevunersen, a potential...

Solid says early data suggest ‘differentiated’ Duchenne...

The company raised $200 million after early findings hinted its therapy could be...

GSK’s 5-in-1 meningococcal shot wins FDA approval

Penmenvy, which protects against five common types of disease-causing bacteria, ...

Beyond copays: Redefining assistance for those with rar...

 Accessia Health helps ease the burden of managing a rare disease or chronic con...

‘It’s not for the faint of heart.’ How 3 CEOs took thei...

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate T...

How Trump’s trade fight could impact the medical device...

Relocating manufacturing would require substantial capital investment, but the t...

Neumora shakes up its C-suite; Biogen cuts early-stage ...

Henry Gosebruch, Neumora’s CEO since 2023, will depart. Elsewhere, Biogen droppe...

Sanofi to take $250M charge on study failure for E. col...

The French drugmaker said the vaccine it agreed to develop with Johnson & Johnso...

A brain biotech launches with Roche’s spare parts

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Thera...

RFK Jr. confirmed by Senate as health secretary

All but one Senate Republican voted for Kennedy, a controversial vaccine critic ...

Sanofi to take $250M charge on study failure for E. Col...

The French drugmaker said the vaccine it agreed to develop with Johnson & Johnso...

Aardvark prices $94M IPO to fund Prader-Willi, obesity ...

Proceeds will support testing of drugs designed to suppress hunger in people wit...

New study offers hints of GLP-1 drugs’ potential in cur...

A small semaglutide trial suggests the medicine's suppression of appetite may ex...

Biogen inks royalty deal to gain funding for lupus drug...

The agreement hands Biogen as much as $250 million in exchange for milestone pay...

Trump orders agencies to plan for ‘large-scale’ job cuts

While Trump’s executive order provides substantial power to Elon Musk’s DOGE eff...

Merck KGaA pursuing Springworks; BridgeBio wins EU drug OK

The German drugmaker confirmed acquisition talks, but cautioned a deal may not m...

Novartis pays $925M to reel in a startup it helped launch

The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and ret...

Vertex COO Arbuckle to step down later this year

Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his rol...

Axsome secures top drug’s future with Teva patent settl...

Shares in the brain drug developer rose by more than 20% Monday on news of the d...

AbbVie, Pfizer gain FDA OK for novel antibiotic

The drug is cleared to treat complicated intra-abdominal infections, including t...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.